Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
ERJ Open Res ; 10(1)2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-38410700

RESUMO

Background: Exacerbations of COPD (ECOPD) have a major impact on patients and healthcare systems across the world. Precise estimates of the global burden of ECOPD on mortality and hospital readmission are needed to inform policy makers and aid preventive strategies to mitigate this burden. The aims of the present study were to explore global in-hospital mortality, post-discharge mortality and hospital readmission rates after ECOPD-related hospitalisation using an individual patient data meta-analysis (IPDMA) design. Methods: A systematic review was performed identifying studies that reported in-hospital mortality, post-discharge mortality and hospital readmission rates following ECOPD-related hospitalisation. Data analyses were conducted using a one-stage random-effects meta-analysis model. This study was conducted and reported in accordance with the PRISMA-IPD statement. Results: Data of 65 945 individual patients with COPD were analysed. The pooled in-hospital mortality rate was 6.2%, pooled 30-, 90- and 365-day post-discharge mortality rates were 1.8%, 5.5% and 10.9%, respectively, and pooled 30-, 90- and 365-day hospital readmission rates were 7.1%, 12.6% and 32.1%, respectively, with noticeable variability between studies and countries. Strongest predictors of mortality and hospital readmission included noninvasive mechanical ventilation and a history of two or more ECOPD-related hospitalisations <12 months prior to the index event. Conclusions: This IPDMA stresses the poor outcomes and high heterogeneity of ECOPD-related hospitalisation across the world. Whilst global standardisation of the management and follow-up of ECOPD-related hospitalisation should be at the heart of future implementation research, policy makers should focus on reimbursing evidence-based therapies that decrease (recurrent) ECOPD.

2.
Influenza Other Respir Viruses ; 18(1): e13240, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-38229871

RESUMO

Background: Throughout the evolution of the COVID-19 pandemic, the severity of the disease has varied. The aim of this study was to determine how patients' comorbidities affected and were related to, different outcomes during this time. Methods: Retrospective cohort study of all patients testing positive for SARS-CoV-2 infection between March 1, 2020, and January 9, 2022. We extracted sociodemographic, basal comorbidities, prescribed treatments, COVID-19 vaccination data, and outcomes such as death and admission to hospital and intensive care unit (ICU) during the different periods of the pandemic. We used logistic regression to quantify the effect of each covariate in each outcome variable and a random forest algorithm to select the most relevant comorbidities. Results: Predictors of death included having dementia, heart failure, kidney disease, or cancer, while arterial hypertension, diabetes, ischemic heart, cerebrovascular, peripheral vascular diseases, and leukemia were also relevant. Heart failure, dementia, kidney disease, diabetes, and cancer were predictors of adverse evolution (death or ICU admission) with arterial hypertension, ischemic heart, cerebrovascular, peripheral vascular diseases, and leukemia also relevant. Arterial hypertension, heart failure, diabetes, kidney, ischemic heart diseases, and cancer were predictors of hospitalization, while dyslipidemia and respiratory, cerebrovascular, and peripheral vascular diseases were also relevant. Conclusions: Preexisting comorbidities such as dementia, cardiovascular and renal diseases, and cancers were those most related to adverse outcomes. Of particular note were the discrepancies between predictors of adverse outcomes and predictors of hospitalization and the fact that patients with dementia had a lower probability of being admitted in the first wave.


Assuntos
COVID-19 , Demência , Diabetes Mellitus , Insuficiência Cardíaca , Hipertensão , Leucemia , Neoplasias , Doenças Vasculares Periféricas , Humanos , COVID-19/epidemiologia , Pandemias , SARS-CoV-2 , Estudos Retrospectivos , Vacinas contra COVID-19 , Fatores de Risco , Diabetes Mellitus/epidemiologia , Hipertensão/epidemiologia , Unidades de Terapia Intensiva , Hospitalização , Neoplasias/complicações , Neoplasias/epidemiologia , Neoplasias/terapia
3.
Emergencias (Sant Vicenç dels Horts) ; 30(2): 84-90, abr. 2018. graf, tab
Artigo em Espanhol | IBECS | ID: ibc-171584

RESUMO

Objetivo. Validar la escala pronóstica EAHFE-3D en una cohorte externa de pacientes atendidos por insuficiencia cardiaca aguda (ICA). Método. Estudio de cohortes multipropósito que incluyó pacientes con ICA en 3 centros hospitalarios del País Vasco entre 2011 y 2013. Se recogieron los datos demográficos (edad), clase funcional basal (New York Heart Association), clínicos (presión arterial sistólica y saturación de oxígeno basal), analíticos (natremia) y terapéuticos (ventilación mecá- nica no invasiva e inotrópicos y vasopresores) en el servicio de urgencias (SU) necesarios para el cálculo de la escala EAHFE-3D. La variable de resultado principal fue la mortalidad a tres días de la llegada al SU. Resultados. Analizamos 717 pacientes con información completa. El intercepto β el modelo fue 0,5 (IC95%: -2,7- 3,7) y la pendiente α fue de 1,3 (IC95%: 0,4-2,2). El área bajo la curva AUC (ROC) fue 0,76 (IC95%: 0,58-0,94). Conclusiones. La escala EAHFE-3D presentó una buena capacidad predictiva en nuestra muestra, no diferente a la obtenida por los autores originales, aunque no ha mostrado buena calibración. Se recomienda continuar con el proceso de validación antes de ser implementada en la práctica clínica (AU)


Objective. To validate the EAHFE-3D scale, based on the Acute Heart Failure in Emergency Departments registry, in a cohort of patients attended for acute heart failure. Methods. Study of a multipurpose cohort of patients with acute heart failure in 3 hospitals in the Basque Country between 2011 and 2013. We extracted age, baseline New York Heart Association functional class, systolic blood pressure, baseline arterial oxygen saturation, sodium level in blood, and emergency department treatments (noninvasive mechanical ventilation, use of inotropic agents and vasopressors) in order to calculate each patient's EAHFE-3D score. The main outcome variable was mortality within 3 days of arrival at the emergency department. Results. The patient sample for score validation consisted of 717 patients with complete information. The model's intercept was 0.5 (95% CI, -2.7 to 3.7) and the slope was 1.3 (95% CI, 0.4 to 2.2). The area under the receiver operating characteristic curve was 0.76 (95% CI, 0.58 to 0.94). Conclusions. The EAHFE-3D scale's ability to discriminate was good in this patient sample and similar to that reported by the authors who developed the scale; however, calibration was poor. The scale should be studied further before it is applied in clinical practice (AU)


Assuntos
Humanos , Insuficiência Cardíaca/diagnóstico , Prognóstico , Índice de Gravidade de Doença , Tomada de Decisão Clínica/métodos , Estudos de Coortes , Curva ROC , 28599 , Intervalos de Confiança
4.
Emergencias ; 30(2): 84-90, 2018.
Artigo em Inglês, Espanhol | MEDLINE | ID: mdl-29547230

RESUMO

OBJECTIVES: To validate the EAHFE-3D scale, based on the Acute Heart Failure in Emergency Departments registry, in a cohort of patients attended for acute heart failure. MATERIAL AND METHODS: Study of a multipurpose cohort of patients with acute heart failure in 3 hospitals in the Basque Country between 2011 and 2013. We extracted age, baseline New York Heart Association functional class, systolic blood pressure, baseline arterial oxygen saturation, sodium level in blood, and emergency department treatments (noninvasive mechanical ventilation, use of inotropic agents and vasopressors) in order to calculate each patient's EAHFE-3D score. The main outcome variable was mortality within 3 days of arrival at the emergency department. RESULTS: The patient sample for score validation consisted of 717 patients with complete information. The model's intercept was 0.5 (95% CI, -2.7 to 3.7) and the slope was 1.3 (95% CI, 0.4 to 2.2). The area under the receiver operating characteristic curve was 0.76 (95% CI, 0.58 to 0.94). CONCLUSION: The EAHFE-3D scale's ability to discriminate was good in this patient sample and similar to that reported by the authors who developed the scale; however, calibration was poor. The scale should be studied further before it is applied in clinical practice.


OBJETIVO: Validar la escala pronóstica EAHFE-3D en una cohorte externa de pacientes atendidos por insuficiencia cardiaca aguda (ICA). METODO: Estudio de cohortes multipropósito que incluyó pacientes con ICA en 3 centros hospitalarios del País Vasco entre 2011 y 2013. Se recogieron los datos demográficos (edad), clase funcional basal (New York Heart Association), clínicos (presión arterial sistólica y saturación de oxígeno basal), analíticos (natremia) y terapéuticos (ventilación mecánica no invasiva e inotrópicos y vasopresores) en el servicio de urgencias (SU) necesarios para el cálculo de la escala EAHFE-3D. La variable de resultado principal fue la mortalidad a tres días de la llegada al SU. RESULTADOS: Analizamos 717 pacientes con información completa. El intercepto ß el modelo fue 0,5 (IC95%: ­2,7- 3,7) y la pendiente α fue de 1,3 (IC95%: 0,4-2,2). El área bajo la curva AUC (ROC) fue 0,76 (IC95%: 0,58-0,94). CONCLUSIONES: La escala EAHFE-3D presentó una buena capacidad predictiva en nuestra muestra, no diferente a la obtenida por los autores originales, aunque no ha mostrado buena calibración. Se recomienda continuar con el proceso de validación antes de ser implementada en la práctica clínica.


Assuntos
Insuficiência Cardíaca/mortalidade , Doença Aguda , Pressão Sanguínea , Serviço Hospitalar de Emergência , Feminino , Insuficiência Cardíaca/sangue , Humanos , Masculino , Oxigênio/sangue , Prognóstico , Sistema de Registros , Respiração Artificial/estatística & dados numéricos , Estudos Retrospectivos , Sódio/sangue , Espanha/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...